August 20, 2015 — The ITM Group announced that its subsidiary ITG GmbH has successfully in-licensed DOTA-Zoledronate, a next-generation theranostic agent for bone targeted radionuclide therapy and diagnostics in patients suffering from bone metastases. DOTA-Zoledronate specifically targets cancerous bone lesions and, when radiolabeled with therapeutic or diagnostic radioisotopes, has shown high potential for positron emission tomography (PET) imaging and endoradiotherapy.
In first studies DOTA-Zoledronate showed a high target to background ratio and a fast clearance pathway. Moreover, the novel bone agent is attractive for tagging of various radionuclides like the generator derived PET-radionuclide Gallium-68, therapeutic beta-emitting no-carrier-added (n.c.a) Lutetium-177 as well as the α-particle emitters Actinium-225 and Bismuth-213.
Due to its versatile properties for radiolabeling, DOTA-Zoledronate is a promising agent for the development of other future-oriented radionuclide therapy concepts for personalized nuclear oncology. Fundamental research into radiolabeled DOTA-Zoledronate conjugates has recently been conducted at the Johannes Gutenberg University Mainz led by the head of the Institute of Nuclear Chemistry, Prof. Frank Rösch.
For more information: www.itg-garching.de
November 12, 2025 
